85 -12 (50) 2022 — Khamzaev K.A.,Kurambaeva S.R. — CLINICAL AND MORPHOLOGICAL PARALLELS OF DIAGNOSIS, TREATMENT AND PROGNOSIS OF IGA NEPHROPATHY IN CHILDREN

CLINICAL AND MORPHOLOGICAL PARALLELS OF DIAGNOSIS, TREATMENT AND PROGNOSIS OF IGA NEPHROPATHY IN CHILDREN

Khamzaev K.A., Tashkent Pediatric Medical Institute

Kurambaeva S.R., Tashkent Pediatric Medical Institute

Madazimova B.D., Tashkent Pediatric Medical Institute

Sobirjonov U.Kh. Tashkent Pediatric Medical Institute

Resume

The study included 43 children with a biopsy-confirmed diagnosis of IgA nephropathy. The mean follow-up period for children after kidney biopsy was 9.2 years (2.2–10.1 years). The study of kidney biopsy specimens revealed the following changes according to the HAAS classification: in 22(56.4%) class I, in 4(10.2%) class II, in 11(28.3%) class III, in 2(5.1%) class IV. Treatment was carried out according to the result of a kidney biopsy and the clinical picture. By the end of the follow-up period, 17(43.6%) children were in remission, 15(38.5%) had minimal changes in urinalysis, 4(10.2%) continued active disease, 3(7.7%) developed chronic stage III kidney disease. The morphological diagnosis of IgA nephropathy in children may not always correlate with the course of the disease and its progression to CKD; further work is required in this direction. Active disease with proteinuria and nephritic syndrome during the observation period is a significant risk factor for poor prognosis and progression of IgA nephropathy in children.

Key words: IgA nephropathy, hematuria, microhematuria, proteinuria.

First page

487

Last page

493

For citation: Khamzaev K.A.,Kurambaeva S.R., Madazimova B.D., Sobirjonov U.Kh. – CLINICAL AND MORPHOLOGICAL PARALLELS OF DIAGNOSIS, TREATMENT AND PROGNOSIS OF IGA NEPHROPATHY IN CHILDREN //New Day in Medicine 12(50)2022 487-493 https://clck.ru/33CRSS

LIST OF REFERENCES:

1. Rodrigues J.C., Haas M., Reich H.N. IgA nephropathy //Clinical Journal of the American Society of Nephrology. – 2017. – Т. 12. – №. 4. – С. 677-686.
2. Schena F.P., Nistor I. Epidemiology of IgA nephropathy: a global perspective //Seminars in nephrology. – WB Saunders, 2018. – Т. 38. – №. 5. – С. 435-442.
3. Nagayama Y. et al. Impact of the new risk stratification in the 2011 Japanese Society of Nephrology clinical guidelines for IgA nephropathy on incidence of early clinical remission with tonsillectomy plus steroid pulse therapy //Clinical and experimental nephrology. – 2015. – Т. 19. – №. 4. – С. 646-652.
4. Woo K.T. et al. The incidence of IgA nephropathy is associated with socioeconomic deprivation //Kidney international. – 2014. – Т. 86. – №. 3. – С. 651-652.
5. Oates A. IgA nephropathy //Adolescents with Chronic Kidney Disease. – Springer, Cham, 2019. – С.107-128.
6. Coppo R., Davin J.C. The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy //Pediatric nephrology. – 2015. – Т. 30. – №. 2. – С. 189-192.
7. Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients //Journal of nephrology. – 2017. – Т. 30. – №. 3. – С. 339-346.
8. Coppo R. et al. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort //Pediatric nephrology. – 2017. – Т. 32. – №. 1. – С. 139-150.
9. Matsushita S. et al. Long-term morbidity of IgA nephropathy in children evaluated with newly proposed remission criteria in Japan //Clinical and experimental nephrology. – 2015. – Т. 19. – №. 6. – С. 1149-1156.
10. Berthoux F., Mohey H., Laurent B., Mariat C., Afiani A. et al. (2011) Predicting the risk for dialysis or death in IgA nephropathy. //Journal of the American Society of Nephrology: JASN 22: 752–761.
11. Goto M., Wakai K., Kawamura T., Ando M., Endoh M. et al. (2009) A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association 24: 3068–3074.
12. Cambier A. et al. Steroid therapy in children with IgA nephropathy //Pediatric Nephrology. – 2019. – С. 1-8.
13. Kamei K. et al. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy //Pediatric Nephrology. – 2015. – Т. 30. – №. 6. – С. 961-967.
14. Tewari R. et al. Correlation of proteinuria with podocyte foot process effacement in IgA nephropathy: an ultrastructural study //Ultrastructural pathology. – 2015. – Т. 39. – №. 2. – С. 147-151
15. Herlitz L.C., Bomback A.S., Stokes M.B., Radhakrishnan J., D’Agati V.D., Markowitz G.S. (2014) IgA nephropathy with minimal change disease. //Clin J Am Soc Nephrol 9:1033–1039
16. Shen H., Gu W., Mao J., Zhu X., Jin X., Fu H., Liu A., Shu Q., Du L. (2015) Clinical characteristics of concomitant nephrotic IgA nephropathy and minimal change disease in children. //Nephron 130: 21–28.
17. Ronkainen J., Ala-Houhala M., Autio-Harmainen H. et al. Long term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. //Pediatr Nephrol. 2006; 21(9): 1266–1273.
18. Haas M. Histology and immunohistology of IgA nephropathy. //J Nephrol. 2005; 18(6):676–680.
19. Pozzi C., Andrulli S., Pani A., Scaini P., Roccatello D., Fogazzi G., Pecchini P., Rustichelli R., Finocchiaro P., Del Vecchio L., Locatelli F: IgA nephropathy with severe chronic renal failure: A randomized controlled trial of corticosteroids and azathioprine. //J Nephrol 26: 86–93, 2013.
20. Magistroni R., D’Agati V.D., Appel G.B., Kiryluk K: New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. //Kidney Int 88: 974–989, 2015.